Table of Contents
Journal of Signal Transduction
Volume 2016 (2016), Article ID 1362407, 8 pages
http://dx.doi.org/10.1155/2016/1362407
Review Article

Thyroid Hormones as Renal Cell Cancer Regulators

1Department of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland
2Institute of Genetics and Biotechnology, Faculty of Biology, Warsaw University, Pawinskiego 5a, 02-106 Warsaw, Poland
3Department of Microwave Safety, Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland
4School of Molecular Medicine, Medical University of Warsaw, Zwirki i Wigury 61, 02-091 Warsaw, Poland
5Institute of Biochemistry and Biophysics, Pawinskiego 5a, 02-106 Warsaw, Poland

Received 28 October 2015; Accepted 23 February 2016

Academic Editor: Leonidas C. Platanias

Copyright © 2016 Łukasz Szymański et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Definition of Renal Cell Cancer—NCI Dictionary of Cancer Terms, National Cancer Institute, http://www.cancer.gov/dictionary.
  2. W.-H. Chow, L. M. Dong, and S. S. Devesa, “Epidemiology and risk factors for kidney cancer,” Nature Reviews Urology, vol. 7, no. 5, pp. 245–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Buczek, B. Escudier, E. Bartnik, C. Szczylik, and A. Czarnecka, “Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1845, no. 1, pp. 31–41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Cheville, C. M. Lohse, H. Zincke, A. L. Weaver, and M. L. Blute, “Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma,” American Journal of Surgical Pathology, vol. 27, no. 5, pp. 612–624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Mattei, R. D. da Silva, D. Sehrt, W. R. Molina, and F. J. Kim, “Targeted therapy in metastatic renal carcinoma,” Cancer Letters, vol. 343, no. 2, pp. 156–160, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Lv, Z. Bai, Z. Liu, P. Luo, and J. Zhang, “Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms,” International Journal of Clinical and Experimental Pathology, vol. 8, pp. 5781–5786, 2015. View at Google Scholar
  7. V. Radha, S. Nambirajan, and G. Swarup, “Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity,” European Journal of Biochemistry, vol. 236, no. 2, pp. 352–359, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Zwick, J. Bange, and A. Ullrich, “Receptor tyrosine kinase signalling as a target for cancer intervention strategies,” Endocrine-Related Cancer, vol. 8, no. 3, pp. 161–173, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Diamond, J. Riches, B. Faltas, S. T. Tagawa, and D. M. Nanus, “Immunologics and chemotherapeutics for renal cell carcinoma,” Seminars in Interventional Radiology, vol. 31, no. 1, pp. 91–97, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Hulbert, “Thyroid hormones and their effects: a new perspective,” Biological Reviews of the Cambridge Philosophical Society, vol. 75, no. 4, pp. 519–631, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Hennemann, R. Docter, E. C. H. Friesema, M. De Jong, E. P. Krenning, and T. J. Visser, “Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability,” Endocrine Reviews, vol. 22, no. 4, pp. 451–476, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Forrest, L. C. Erway, L. Ng, R. Altschuler, and T. Curran, “Thyroid hormone receptor β is essential for development of auditory function,” Nature Genetics, vol. 13, no. 3, pp. 354–357, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Wikström, C. Johansson, C. Saltó et al., “Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor α1,” The EMBO Journal, vol. 17, no. 2, pp. 455–461, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Oetting and P. M. Yen, “New insights into thyroid hormone action,” Best Practice and Research in Clinical Endocrinology and Metabolism, vol. 21, no. 2, pp. 193–208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S.-Y. Cheng, J. L. Leonard, and P. J. Davis, “Molecular aspects of thyroid hormone actions,” Endocrine Reviews, vol. 31, no. 2, pp. 139–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. L. C. Moeller and D. Führer, “Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective,” Endocrine-Related Cancer, vol. 20, no. 2, pp. R19–R29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Puzianowska-Kuznicka, M. Pietrzak, O. Turowska, and A. Nauman, “Thyroid hormones and their receptors in the regulation of cell proliferation,” Acta Biochimica Polonica, vol. 53, no. 4, pp. 641–650, 2006. View at Google Scholar · View at Scopus
  18. P. M. Yen, “Physiological and molecular basis of thyroid hormone action,” Physiological Reviews, vol. 81, no. 3, pp. 1097–1142, 2001. View at Google Scholar · View at Scopus
  19. W. G. Kim and S.-Y. Cheng, “Thyroid hormone receptors and cancer,” Biochimica et Biophysica Acta—General Subjects, vol. 1830, no. 7, pp. 3928–3936, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Hagenkord, Z. Gatalica, E. Jonasch, and F. A. Monzon, “Clinical genomics of renal epithelial tumors,” Cancer Genetics, vol. 204, no. 6, pp. 285–297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-Y. Cheng, “Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors,” Reviews in Endocrine and Metabolic Disorders, vol. 1, no. 1, pp. 9–18, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. N. J. McKenna, R. B. Lanz, and B. W. O'Malley, “Nuclear receptor coregulators: cellular and molecular biology,” Endocrine Reviews, vol. 20, no. 3, pp. 321–344, 1999. View at Google Scholar · View at Scopus
  23. V. K. K. Chatterjee, “Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor γ resistance,” Biochemical Society Transactions, vol. 29, no. 2, pp. 227–231, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. O. Martínez-Iglesias, S. Garcia-Silva, S. P. Tenbaum et al., “Thyroid hormone receptor β1 acts as a potent suppressor of tumor invasiveness and metastasis,” Cancer Research, vol. 69, no. 2, pp. 501–509, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. J. Guigon and S.-Y. Cheng, “Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis,” Molecular and Cellular Endocrinology, vol. 308, no. 1-2, pp. 63–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Iwasaki, N. Sunaga, Y. Tomizawa et al., “Epigenetic inactivation of the thyroid hormone receptor β1 gene at 3p24.2 in lung cancer,” Annals of Surgical Oncology, vol. 17, no. 8, pp. 2222–2228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Sato, K. Muraishi, J. Tani et al., “Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma,” Endocrine Journal, vol. 57, no. 10, pp. 873–880, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Verga Falzacappa, V. Patriarca, B. Bucci et al., “The TRβ1 is essential in mediating T3 action on Akt pathway in human pancreatic insulinoma cells,” Journal of Cellular Biochemistry, vol. 106, no. 5, pp. 835–848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Martínez-Iglesias, S. García-Silva, J. Regadera, and A. Aranda, “Hypothyroidism enhances tumor invasiveness and metastasis development,” PLoS ONE, vol. 4, no. 7, Article ID e6428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Furuya, J. A. Hanover, and S.-Y. Cheng, “Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 6, pp. 1780–1785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Master, A. Wójcicka, A. Piekiełko-Witkowska et al., “Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1802, no. 11, pp. 995–1005, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K.-H. Tsui, W.-C. Hsieh, M.-H. Lin, P.-L. Chang, and H.-H. Juang, “Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2,” The Prostate, vol. 68, no. 6, pp. 610–619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Shibusawa, K. Hashimoto, A. A. Nikrodhanond et al., “Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo,” The Journal of Clinical Investigation, vol. 112, no. 4, pp. 588–597, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. KEGG PATHWAY: Thyroid Hormone Signaling Pathway—Homo sapiens (Human), http://www.genome.jp/kegg-bin/show_pathway?org_name=hsa&mapno=04919&mapscale=&show_description=hide.
  35. J. H. D. Bassett, C. B. Harvey, and G. R. Williams, “Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions,” Molecular and Cellular Endocrinology, vol. 213, no. 1, pp. 1–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. H.-Y. Lin, M. Sun, H.-Y. Tang et al., “L-thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase,” The American Journal of Physiology—Cell Physiology, vol. 296, no. 5, pp. C980–C991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. P. J. Davis, F. Goglia, and J. L. Leonard, “Nongenomic actions of thyroid hormone,” Nature Reviews Endocrinology, vol. 12, pp. 111–121, 2016. View at Google Scholar
  38. M. Yalcin, D. J. Bharali, L. Lansing et al., “Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts,” Anticancer Research, vol. 29, no. 10, pp. 3825–3831, 2009. View at Google Scholar · View at Scopus
  39. E. Porlan, O. G. Vidaurre, and A. Rodríguez-Peña, “Thyroid hormone receptor-β (TRβ1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2,” Oncogene, vol. 27, no. 19, pp. 2795–2800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. González-Sancho, A. Figueroa, M. López-Barahona, E. López, H. Beug, and A. Muñoz, “Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells,” Molecular Carcinogenesis, vol. 34, no. 1, pp. 25–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Pachucki, M. Ambroziak, Z. Tanski, J. Luczak, J. Nauman, and A. Nauman, “Type I 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma,” Journal of Endocrinological Investigation, vol. 24, no. 4, pp. 253–261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Kamiya, M. Puzianowska-Kuznicka, P. McPhie, J. Nauman, S.-Y. Cheng, and A. Nauman, “Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma,” Carcinogenesis, vol. 23, no. 1, pp. 25–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. S.-Y. Cheng, “Thyroid hormone receptor mutations in cancer,” Molecular and Cellular Endocrinology, vol. 213, no. 1, pp. 23–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. M. D. Rosen, I. H. Chan, and M. L. Privalsky, “Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas,” Molecular Endocrinology, vol. 25, no. 8, pp. 1311–1325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. D. Rosen and M. L. Privalsky, “Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity,” Molecular Endocrinology, vol. 23, no. 8, pp. 1183–1192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Otto and J. Fandrey, “Thyroid hormone induces hypoxia-inducible factor 1α gene expression through thyroid hormone receptor β/retinoid X receptor α-dependent activation of hepatic leukemia factor,” Endocrinology, vol. 149, no. 5, pp. 2241–2250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Chen, Y. Ye, H. Yang et al., “Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays,” International Journal of Cancer, vol. 125, no. 10, pp. 2342–2348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Puzianowska-Kuznicka, A. Nauman, A. Madej, Z. Tanski, S.-Y. Cheng, and J. Nauman, “Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma,” Cancer Letters, vol. 155, no. 2, pp. 145–152, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Wojcicka, A. Piekielko-Witkowska, H. Kedzierska et al., “Epigenetic regulation of thyroid hormone receptor beta in renal cancer,” PLoS ONE, vol. 9, no. 5, Article ID e97624, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Sunitinib versus interferon alfa in metastatic renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. B. I. Rini, I. Tamaskar, P. Shaheen et al., “Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib,” Journal of the National Cancer Institute, vol. 99, no. 1, pp. 81–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Illouz, D. Braun, C. Briet, U. Schweizer, and P. Rodien, “Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors,” European Journal of Endocrinology, vol. 171, no. 3, pp. R91–R99, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Daimon, T. Kato, W. Kaino et al., “Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma,” Japanese Journal of Clinical Oncology, vol. 42, no. 8, Article ID hys076, pp. 742–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Wong, L. S. Rosen, M. Mulay et al., “Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity,” Thyroid, vol. 17, no. 4, pp. 351–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. A. K. Salem, M. S. Fenton, K. M. Marion, and J. M. Hershman, “Effect of sunitinib on growth and function of FRTL-5 thyroid cells,” Thyroid, vol. 18, no. 6, pp. 631–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Shinohara, M. Takahashi, T. Kamishima et al., “The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma,” British Journal of Cancer, vol. 104, no. 2, pp. 241–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Mannavola, P. Coco, G. Vannucchi et al., “A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 9, pp. 3531–3534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Pani, F. Atzori, G. Baghino et al., “Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?” Thyroid, vol. 25, no. 11, pp. 1255–1261, 2015. View at Publisher · View at Google Scholar
  59. F. Baffert, T. Le, G. Thurston, and D. M. McDonald, “Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 290, no. 1, pp. H107–H118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Kamba, B. Y. Y. Tam, H. Hashizume et al., “VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 290, no. 2, pp. H560–H576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. M. A. Skinner, S. D. Safford, and A. J. Freemerman, “RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571,” Anticancer Research, vol. 23, no. 5, pp. 3601–3606, 2003. View at Google Scholar · View at Scopus
  62. F. B. Davis, H.-Y. Tang, A. Shih et al., “Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells,” Cancer Research, vol. 66, no. 14, pp. 7270–7275, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Schmidinger, U. M. Vogl, M. Bojic et al., “Hypothyroidism in patients with renal cell carcinoma: blessing or curse?” Cancer, vol. 117, no. 3, pp. 534–544, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. L. M. Riesenbeck, S. Bierer, I. Hoffmeister et al., “Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib,” World Journal of Urology, vol. 29, no. 6, pp. 807–813, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Liwanpo, C. Ro, S. Haq, and J. M. Hershman, “Sunitinib does not block thyroid peroxidase in patients,” Thyroid, vol. 24, no. 8, pp. 1325–1326, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. O. Bozkurt, H. Karaca, I. Hacıbekiroglu et al., “Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?” Journal of Chemotherapy, 2015. View at Publisher · View at Google Scholar
  67. D. Kust, M. Prpić, J. Murgić et al., “Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy,” Anticancer Research, vol. 34, no. 6, pp. 3177–3184, 2014. View at Google Scholar · View at Scopus
  68. A. Nearchou, A. Valachis, P. Lind, O. Akre, and P. Sandström, “Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a literature-based meta-analysis,” Clinical Genitourinary Cancer, vol. 13, no. 4, pp. 280–286, 2015. View at Publisher · View at Google Scholar
  69. P. Poplawski and A. Nauman, “Thyroid hormone—triiodothyronine—has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1)—role of E2F4, E2F5 and p107, p130,” Thyroid Research, vol. 1, no. 1, article 5, 2008. View at Publisher · View at Google Scholar
  70. K. Sterling, D. Bellabarba, E. S. Newman, and M. A. Brenner, “Determination of triiodothyronine concentration in human serum,” The Journal of Clinical Investigation, vol. 48, no. 6, pp. 1150–1158, 1969. View at Publisher · View at Google Scholar · View at Scopus
  71. J. E. H. Stafford, S. Lees, and D. Watson, “Serum triiodothyronine determination in clinical use,” Journal of Clinical Pathology, vol. 29, no. 7, pp. 642–647, 1976. View at Publisher · View at Google Scholar · View at Scopus
  72. P. R. Larsen, “Direct immunoassay of triiodothyronine in human serum,” The Journal of Clinical Investigation, vol. 51, no. 8, pp. 1939–1949, 1972. View at Publisher · View at Google Scholar · View at Scopus
  73. J. A. Nauman, A. Nauman, and S. C. Werner, “Total and free triiodothyronine in human serum,” The Journal of Clinical Investigation, vol. 46, no. 8, pp. 1346–1355, 1967. View at Publisher · View at Google Scholar